An executive at AstraZeneca says breast-cancer drugs that the company highlighted at an industry conference over the weekend could represent $10 billion worth of company sales in five years’ time.
U.S. stocks remain a strong bet, thanks to a resilient consumer, says this European wealth manager
Investors are climbing a “wall of worry,” when it comes to all-important U.S. assets. That shouldn’t deter them, says Indosuez Wealth…
